Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.81 EUR
Change Today -0.069 / -7.89%
Volume 7.0K
0JV On Other Exchanges
Symbol
Exchange
Berlin
NYSE Amex
As of 1:42 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

ibio inc (0JV) Snapshot

Open
€0.84
Previous Close
€0.87
Day High
€0.86
Day Low
€0.78
52 Week High
10/20/14 - €2.85
52 Week Low
06/13/14 - €0.26
Market Cap
59.6M
Average Volume 10 Days
14.9K
EPS TTM
--
Shares Outstanding
74.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IBIO INC (0JV)

Related News

No related news articles were found.

ibio inc (0JV) Related Businessweek News

No Related Businessweek News Found

ibio inc (0JV) Details

iBio, Inc., a biotechnology company, focuses on the commercialization of its proprietary plant-based protein expression technologies in the United States and internationally. Its proprietary technologies include iBioLaunch, a transformative platform technology for the development and production of therapeutic proteins and vaccines; and iBioModulator, a technology platform that enhances the potency and duration of the effect of prophylactic and therapeutic vaccines. The company’s product candidates comprise IBIO-CFB03, a product for treatment of idiopathic pulmonary fibrosis; C1 Esterase Inhibitor, a plasma-derived protein; Alpha-Galactosidase, an enzyme replacement protein; and Palivizumab, a monoclonal antibody for the therapeutic protein market. Its vaccine products include H1N1 Influenza and H5N1 Influenza products that have completed Phase I human clinical trials, as well as yellow fever vaccine; malaria and hookworm parasitic pathogen vaccines; and human papillomavirus therapeutic vaccine. The company’s product candidates also comprise Anthrax/Plague bacterial disease vaccine; and Anthrax, a monoclonal antibody for the biodefense market. It has strategic alliances and collaborations with various companies, such as Fraunhofer Center for Molecular Biology, GE Healthcare, FioCruz, and Caliber Biotherapeutics LLC. The company is headquartered in Newark, Delaware.

7 Employees
Last Reported Date: 09/29/14

ibio inc (0JV) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $300.0K
President
Total Annual Compensation: $230.0K
Chief Financial Officer
Total Annual Compensation: $22.0K
Chief Scientific Officer
Total Annual Compensation: $200.0K
Compensation as of Fiscal Year 2014.

ibio inc (0JV) Key Developments

iBio, Inc. Arranges Production of iBio CFB03 for Clinical Development with Caliber Biotherapeutics

iBio Inc. has engaged Caliber Biotherapeutics LLC to scale-up and produce materials for clinical development of the first of iBio's proprietary anti-fibrosis products, IBIO-CFB03. Caliber's production will be used for IND-enabling toxicology studies and initial human clinical trials of IBIO-CFB03. The expansion in 2014 of iBio's exclusive technology collaboration with Novici Biotech LLC broadened iBio's fibrosis therapeutics program through a combination of the strengths of iBio's proprietary iBioLaunch(TM) platform technology with Novici's patented optimization technology. iBio then engaged CBR International Corporation for strategic regulatory and clinical services and assembled a Clinical Advisory Board of internationally recognized experts in fibrotic diseases to assist the company in clinical product development and human trial design.

iBio, Inc. announced delayed 10-Q filing

On 02/17/2015, iBio, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Levi & Korsinsky Announces Class Action Lawsuit iBio, Inc

Levi & Korsinsky announced that a class action lawsuit has been commenced in the United States District Court for the District of Delaware on behalf of investors who purchased iBio, Inc. securities between October 13, 2014 and October 23, 2014. The complaint alleges that during the class period, the company issued materially false and misleading statements to investors by wrongfully suggesting that the company's launch platform patents and related proprietary technology would be licensed by the makers of the experimental Ebola drug, ZMapp. The complaint alleges that when the true facts were revealed, the price of the company's stock fell significantly, damaging investors.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
0JV:GR €0.81 EUR -0.069

0JV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 0JV.
View Industry Companies
 

Industry Analysis

0JV

Industry Average

Valuation 0JV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 48.4x
Price/Book 7.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 44.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IBIO INC, please visit www.ibioinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.